By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1
Have you heard that we launched a podcast? It’s true! Cell & Gene: The Podcast is available anywhere you get your podcasts, and trust me, it’s a can’t-miss. Every other week, I’ll interview a subject matter expert in the cell and gene therapy space about what they’re working on, how it’s moving the sector forward, and what’s next on their professional roadmap.
The first episode is live, and in it, I talk to Enzyvant’s CEO, Rachelle Jacques about her path to Enzyvant and whether being the leader of a biotech was always her plan. Rachelle and I talk through how her background in business has helped her to stear Enzyvant as it continues to develop regenerative therapies for people with rare diseases. And, of course, we cover Enzyvant’s lead asset, investigational regenerative therapy RVT-802 for congenital athymia. Rachelle offers insightful information about the future of tissue-based therapies and what they mean to the world of rare diseases.
Subscribe today and contact me with ideas and suggestions for topics you’d like us to cover on Cell & Gene: The Podcast. In the meantime, happy listening!